EGFR and non-small cell lung carcinoma: Although the prognosis of patients with driver mutations has improved, the molecular features are not taken into consideration in these scores, and it is difficult to accurately predict the prognosis of patients with BM of NSCLC with EGFR mutations and ALK rearrangements.